Abbott Laboratories (ABT) $107.96
Abbott is charging toward its 200-day moving average after a blistering 29% quarterly rally, but technical exhaustion at these levels suggests the easy money has already been made.
52-wk High $137.49
📌 Investment Snapshot
- Trading at $107.96 with a 34.3x P/E ratio reflecting high growth expectations.
- Q1 2026 revenue hit $11.16B with EPS of $0.62 amid medical device strength.
- Three unfilled bullish Fair Value Gaps (FVG) remain below the current price.
- Wall Street consensus maintains a ‘Buy’ with a $118.42 mean price target.
⏳ WAIT
Abbott has reclaimed its SMA200 but sits in overbought territory with an RSI of 68.8. The stock needs to consolidate its recent 29% three-month gain before offering a safe entry.
| 📍 Entry Zone | $103.38 or below | 🛑 Stop-Loss | $98.50 |
| 📋 Adjust If | RSI drops below 40 or Q3 guidance is raised. | ||
The Investment Case — Why Now?
Over the last 90 days, Abbott transitioned from a laggard to a momentum leader as institutional buying accelerated following the May 11th anchored VWAP floor. The market is clearly re-rating the medical device segment’s recovery, evidenced by the 13.4% return over the past month alone.
Despite the optimism, the 34.3x P/E multiple demands flawless execution in an environment where the 10Y Treasury yield sits at 4.67%. Any deceleration in free cash flow, which recently printed at $0.9B, could trigger a sharp valuation reset toward the $90 Volume Profile POC.
Can Abbott sustain a premium valuation if the 10Y Treasury remains above 4.5% through year-end?
🤔 Can Abbott sustain a premium valuation if the 10Y Treasury remains above 4.5% through year-end?
🏢 Company Overview
| Detail | Value |
|---|---|
| Sector | Healthcare |
| Industry | Medical Devices |
| Dividend Yield | 2.38% |
| Short Float | 1.6% |
Open chart on TradingView →
📈 Price Action & Technicals
Golden Cross
Inside VA
Buy-side Sweep at $89.97 on 2026-07-15
Abbott is currently wrestling with its SMA200 at $106.56, a level that has historically acted as a pivot for long-term trend direction. While the stock has successfully closed above this marker, the steep angle of the SMA50 ($94.4) suggests a period of mean reversion is likely.
The RSI at 68.8 signals that the recent vertical move is reaching a point of exhaustion. Although the MACD remains in a bullish configuration at 3.85, the narrowing gap between the signal line warns of a potential momentum crossover in the coming sessions.
Price action is currently trading near the upper Bollinger Band of $113.65, further confirming that the stock is stretched relative to its short-term average. The anchored VWAP at $92.36 remains the ultimate institutional line in the sand for this rally.
Recent liquidity sweeps at $89.97 and $94.54 cleared out weak-handed shorts, providing the fuel for the current breakout. However, the lack of recent sell-side sweeps at higher prices suggests that large-scale distribution hasn’t yet commenced.
Historically, when ABT reaches an ADX of 41.9 alongside an overbought RSI, the stock undergoes a 5-8% pullback to test previous breakout zones. We expect a retest of the $103.38 bullish FVG before any sustainable move toward the $118 consensus target.
⚖ Peer P/E Comparison
| Ticker | Company | P/E (TTM) |
|---|---|---|
| ABT | Abbott Laboratories | 34.3x |
| SYK | Stryker Corp | 38.1x |
| MDT | Medtronic PLC | 26.4x |
| BSX | Boston Scientific | 32.8x |
| SPY | S&P 500 Avg | 21.5x |
💰 Earnings Deep Dive
| Period | Revenue | EPS | YoY |
|---|---|---|---|
| Q1 2026 | $11.16B | $0.62 | +0.2% |
| Q4 2025 | $11.46B | $1.02 | +1.5% |
| Q3 2025 | $11.37B | $0.95 | -0.8% |
| Q2 2025 | $11.14B | $1.02 | +2.1% |
Abbott generated $0.9B in Free Cash Flow last quarter, supporting a $0.2B buyback program and a consistent 2.38% dividend yield.
Revenue has remained remarkably stable between $11.1B and $11.4B over the last four quarters, though EPS volatility in Q1 2026 ($0.62) reflects seasonal margin pressure. The market is looking for a breakout from this $11B revenue floor in the upcoming October report.
🚀 Growth Drivers — What Moves the Stock
- FreeStyle Libre Expansion 🟢 Upside Surprise — Next-gen glucose monitoring adoption in international markets continues to outpace domestic growth.
- Elective Surgery Recovery 🟡 Priced In — Post-pandemic surgical volumes have finally stabilized, driving consistent demand for cardiovascular devices.
- M&A Pipeline 🟢 Upside Surprise — With $0.9B in quarterly FCF, Abbott is well-positioned for bolt-on acquisitions in the structural heart space.
🏦 Smart Money & Institutional Positioning
13F Holdings
| Institution | Shares (K) |
|---|---|
| Blackrock Inc. | 145,687 |
| Vanguard Capital Management LLC | 112,949 |
| State Street Corporation | 79,575 |
Holdings reflect most recent 13F (45-day lag).
Insider Transactions
| Name | Title | Date | Type | Shares |
|---|---|---|---|---|
| STRATTON JOHN G. | Director | 2026-05-07 | Purchase | 2000 |
| STARKS DANIEL J | Director | 2026-04-27 | Purchase | 10000 |
Short Interest
| Short % Float | Days to Cover |
|---|---|
| 1.6% | 1.8 |
⚠ Key Risk Factors
~$1.2B impact
Valuation compression
🤔 Is the market underestimating the long-term disruption of GLP-1 drugs on Abbott’s core device business?
🎯 Guidance & Wall Street View
Management maintains a positive outlook for the second half of 2026, citing robust demand for the FreeStyle Libre 3 system.
| High Target | Mean Target | Low Target | Analysts | Consensus |
|---|---|---|---|---|
| $135.00 | $118.42 | $103.00 | 24 | Buy |
| Firm | Rating | Target | Date | Action |
|---|---|---|---|---|
| UBS | Buy | $118.42 | 2026-07-28 | Maintained |
| JP Morgan | Overweight | $118.42 | 2026-07-17 | Maintained |
Analysts remain overwhelmingly bullish with 24 ‘Buy’ ratings, though the current price is rapidly approaching the average target.
Open chart on TradingView →
📊 Bull vs Bear — Probability-Weighted Scenarios
🐂 Bull Case
- FreeStyle Libre 3 dominates the CGM market with superior margins.
- Successful integration of recent cardiovascular acquisitions drives double-digit growth.
📊 Base Case
Abbott grows revenue at mid-single digits while maintaining its 2.38% dividend yield.
🐻 Bear Case
- GLP-1 drugs significantly reduce the patient pool for heart and diabetes devices.
- Multiple contraction occurs as investors rotate into higher-yielding fixed income.
🎯 Investor Action Plan — By Profile
The stock is overextended after a 13% monthly run. Wait for a pullback to the $101.90-$103.38 FVG zone to manage risk-reward effectively.
Maintain existing positions but avoid adding here. The Technical Confluence Score of 100 is impressive, but RSI divergence suggests a cooling period is imminent.
Abbott is a core healthcare holding, but buying at a 34x P/E near 52-week resistance is suboptimal. Look for entries closer to the $92 VWAP.
If you’re interested in the Healthcare sector, also read:
❓ Investor FAQ — People Also Ask
Q: Why is ABT stock rising despite high interest rates?
Investors are rotating into high-quality healthcare names with strong cash flows and defensive characteristics as economic uncertainty persists.
Q: What is the key support level for Abbott?
The primary support level is the SMA200 at $106.56, followed by the significant Volume Profile POC at $90.07.
Q: Is the dividend safe?
Yes, with a payout ratio supported by $0.9B in quarterly free cash flow and a long history of dividend growth, the 2.38% yield is secure.
📖 New to these terms? P/E Ratio · Free Cash Flow · Insider Signals · Stop-Loss · RSI
📊 For real-time updates and advanced charting tools,
📋 Disclaimer
This analysis is for informational purposes only and does not constitute financial advice. Abbott Laboratories’ performance is subject to regulatory risks and market volatility.
All active positions and their real-time performance are tracked on our Investment Log.
#ABT #AbbottLaboratories #MedicalDevices #StockMarket #Investing #HealthcareStocks #WallStreet #TechnicalAnalysis